The trademark IMZONTIX was filed by AstraZeneca AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on January 23, 2013, and received one opposition filed on April 23, 2013 by GlaxoSmithKline Biologicals S.A. on Likelihood of confusion. and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued April 23, 2013
It was designated 'Basic Application' for International Application 1146683 at the World Intellectual Property Organization (WIPO).
The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on December 31, 2012.